已收盘 02-24 16:00:00 美东时间
0.000
0.00%
AstraZeneca (NASDAQ:AZN) announced on Tuesday that a blood pressure therapy it acquired through its 2023 acquisition of CinCor Pharma has reached its primary goal in a Phase 3 trial, offering new hope...
2025-10-07 19:47
AstraZeneca (NASDAQ:AZN) plans to submit regulatory filings for its blood pressure treatment baxdrostat by the end of this year, seeking approval for the small molecule therapy potentially in 2026, Re...
2025-08-31 00:03